ICU Medical/$ICUI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ICU Medical
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
Ticker
$ICUI
Sector
Primary listing
Employees
15,000
Headquarters
Website
ICU Medical Metrics
BasicAdvanced
$3.3B
-
-$1.51
0.86
-
Price and volume
Market cap
$3.3B
Beta
0.86
52-week high
$181.06
52-week low
$107.00
Average daily volume
363K
Financial strength
Current ratio
2.444
Quick ratio
1.014
Long term debt to equity
63.226
Total debt to equity
66.404
Interest coverage (TTM)
1.15%
Profitability
EBITDA (TTM)
331.339
Gross margin (TTM)
35.84%
Net profit margin (TTM)
-1.56%
Operating margin (TTM)
5.21%
Effective tax rate (TTM)
332.40%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
1.84%
Return on equity (TTM)
-1.78%
Valuation
Price to revenue (TTM)
1.376
Price to book
1.55
Price to tangible book (TTM)
-39.02
Price to free cash flow (TTM)
64.62
Free cash flow yield (TTM)
1.55%
Free cash flow per share (TTM)
2.058
Growth
Revenue change (TTM)
2.96%
Earnings per share change (TTM)
-48.47%
3-year revenue growth (CAGR)
10.04%
10-year revenue growth (CAGR)
22.15%
3-year earnings per share growth (CAGR)
83.86%
10-year earnings per share growth (CAGR)
-4.16%
What the Analysts think about ICU Medical
Analyst ratings (Buy, Hold, Sell) for ICU Medical stock.
Bulls say / Bears say
ICU Medical’s Q2 2025 revenue reached $548.87 million, beating the $542.50 million consensus, and adjusted EPS was $2.10, surpassing expectations by $0.60, showing strong operational performance (Reuters)
In Q1 2025, consumables revenue increased 9.1% to $266.2 million and infusion systems revenue rose 5.7% to $166.3 million year-over-year, indicating ongoing demand in core markets (Form 10-Q, June 30 2025) (SEC)
GAAP gross margin improved to 35% in Q1 2025 from 33% in Q1 2024, signaling efficiency gains before the IV Solutions joint venture closing (GlobeNewswire)
Vital Care segment revenue fell 34% year-over-year in Q2 2025 after the deconsolidation of the Otsuka joint venture, pointing to structural challenges in a key business line (Investing.com)
The U.S. Food and Drug Administration sent a warning letter in April 2025 regarding unauthorized changes to Medfusion and CADD infusion pumps, introducing regulatory risk and the possibility of enforcement actions for ICU Medical (MedTech Dive)
ICU Medical narrowed its full-year 2025 adjusted EPS guidance to $6.85–$7.15, signifying limited earnings visibility as tariff issues and ongoing integration challenges persist (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
ICU Medical Financial Performance
Revenues and expenses
ICU Medical Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ICU Medical stock?
ICU Medical (ICUI) has a market cap of $3.3B as of September 19, 2025.
What is the P/E ratio for ICU Medical stock?
The price to earnings (P/E) ratio for ICU Medical (ICUI) stock is 0 as of September 19, 2025.
Does ICU Medical stock pay dividends?
No, ICU Medical (ICUI) stock does not pay dividends to its shareholders as of September 19, 2025.
When is the next ICU Medical dividend payment date?
ICU Medical (ICUI) stock does not pay dividends to its shareholders.
What is the beta indicator for ICU Medical?
ICU Medical (ICUI) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.